In what it claimed as an “Australian first”, Vitura Health has supplied GMP psilocybin for therapeutic use by a patient outside of a clinical trial under the Authorised Prescriber (AP) scheme.
Last year, Vitura announced Cortexa, a 50:50 joint venture with PharmAla Biotech under which it has exclusive rights to buy and distribute the Canada-based research and development firm’s GMP-manufactured psychedelic products in Australia.
Join the Cannabiz revolution
Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?
This article is included with our Premium subscription.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Vel turpis nunc eget lorem dolor sed. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Nisl nunc mi ipsum faucibus vitae.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.